Symmetrix Biotech Profile
Key Indicators
- Authorised Capital ₹ 65.00 Cr
as on 17-07-2024
- Paid Up Capital ₹ 49.51 Cr
as on 17-07-2024
- Company Age 17 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.45 Cr
as on 17-07-2024
- Satisfied Charges ₹ 12.00 Cr
as on 17-07-2024
- Revenue -44.71%
(FY 2023)
- Profit -156.29%
(FY 2023)
- Ebitda -72.54%
(FY 2023)
- Net Worth 6.35%
(FY 2023)
- Total Assets -7.93%
(FY 2023)
About Symmetrix Biotech
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 65.00 Cr and a paid-up capital of Rs 49.51 Cr.
The company currently has active open charges totaling ₹5.45 Cr. The company has closed loans amounting to ₹12.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Jayant Ranade, Nirmal Mulye, Yatindra Prashar, and Three other members serve as directors at the Company.
- CIN/LLPIN
U24239MH2007PTC167239
- Company No.
167239
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Jan 2007
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Andheri East, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Symmetrix Biotech?
Board Members(6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nirmal Mulye  | Director | 16-Jun-2009 | Current |
Jayant Ranade  | Director | 24-Jan-2007 | Current |
| Yatindra Prashar | Director | 16-Jun-2009 | Current |
| Kaushik Vyas | Director | 03-Aug-2021 | Current |
| Rama Marathe | Director | 08-Mar-2013 | Current |
| Shraddha Dhamankar | Director | 24-Jan-2007 | Current |
Financial Performance and Corporate Structure Insights of Symmetrix Biotech.
Symmetrix Biotech Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 44.71% decrease. The company also saw a substantial fall in profitability, with a 156.29% decrease in profit. The company's net worth moved up by a moderate rise of 6.35%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Symmetrix Biotech?
In 2023, Symmetrix Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Nli Healthcare (India) Private LimitedActive 5 years 10 monthsJayant Ranade, Nirmal Mulye and 1 more are mutual person
- Enem Nostrum Remedies Private LimitedActive 23 years 11 months
Nirmal Mulye and Shraddha Dhamankar are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Biotechnology Industry Research Assistance Council Creation Date: 28 Mar 2014 | ₹5.45 Cr | Open |
Technology Development Board Creation Date: 22 Jul 2013 | ₹12.00 Cr | Satisfied |
How Many Employees Work at Symmetrix Biotech?
Symmetrix Biotech has a workforce of 2 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Symmetrix Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Symmetrix Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
